[go: up one dir, main page]

AR065657A1 - DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. - Google Patents

DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.

Info

Publication number
AR065657A1
AR065657A1 ARP080100964A ARP080100964A AR065657A1 AR 065657 A1 AR065657 A1 AR 065657A1 AR P080100964 A ARP080100964 A AR P080100964A AR P080100964 A ARP080100964 A AR P080100964A AR 065657 A1 AR065657 A1 AR 065657A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
arthritis
halo
alkyl
cartilage
Prior art date
Application number
ARP080100964A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR065657A1 publication Critical patent/AR065657A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de 4-oxo-tiazol, composiciones farmacéuticas y método para su preparacion y su uso en medicamentos para tratar una afeccion incluyendo sin carácter limitativo espondilitis anquilosante, ateroesclerosis, artritis (tales como artritis reumatoide, artritis infecciosa, artritis de la ninez, artritis psoriásica, artritis reactiva), enfermedades relacionadas con los huesos (incluyendo aquellas relacionadas con la formacion de los huesos), cáncer de mama (incluyendo aquellos que no responden a la terapia anti-estrogénica) trastornos /cardiovasculares, enfermedades relacionadas con los cartílagos (tales como lesion/pérdida de cartílagos, degeneracion de cartílagos, y aquellas relacionadas con la formacion de cartílagos), condrodisplasia, condrosarcoma, lesion cronica de espalda, bronquitis cronica, enfermedad cronica inflamatoria de las vías aéreas, enfermedad pulmonar obstructiva cronica, diabetes, trastornos de homeostasis de energía, gota, pseudogota, trastornos de los lípidos, síndrome metabolico, mieloma multiple, obesidad, osteoartritis, osteogénesis imperfecta, metástasis osea osteolítica, osteomalacia, osteoporosis, enfermedad de Paget, enfermedad periodontal, polimialgia reumática, síndrome de Reiter, lesion por estrés reiterado, hiperglucemia, nivel elevado de glucosa en sangre, y resistencia a la insulina. Reivindicacion 1: Un compuesto de formula (1) en el cual X es S u O; R1 es halo, alquilo C1-4 sustituido en forma opcional, alcoxi C1-4 sustituido en forma opcional, o hidroxilo; R2 se selecciona de alquilo C1-3 sustituido por halo, ciano, halo, -C(O)NH2, y -C(O)O-alquilo C1-4, o en forma alternativa R2 está unido junto a R3 para formar un arilo fusionado al anillo fenilo al cual R2 y R3 se muestran unidos; R3 es H, o en forma alternativa R3 está unido junto a R2 para formar un arilo fusionado al anillo fenilo al cual R3 y R2 se muestran unidos; R4 es halo, ciano, alquilo C1-3 sustituido por halo, -CsCH, -C(O)O-alquilo C1-4, -C(O)NH2 o -S(O2)-alquilo C1-4; y R5 y R6 se seleccionan en forma independiente de H, alquilo C1-4 sustituido en forma opcional, heteroarilo sustituido en forma opcional, y heterociclilo sustituido en forma opcional, o en forma alternativa R5 y R6 están ligados junto con el átomo N al cual están unidos para formar un heterociclilo que contiene N sustituido en forma opcional; y o un isomero optico, enantiomero, diasteromero, cis-trans isomero, racemato, profármaco o sales aceptables desde el punto de vista farmacéutico de los anteriores.
ARP080100964A 2007-03-07 2008-03-07 DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. AR065657A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89346407P 2007-03-07 2007-03-07

Publications (1)

Publication Number Publication Date
AR065657A1 true AR065657A1 (es) 2009-06-24

Family

ID=39530136

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100964A AR065657A1 (es) 2007-03-07 2008-03-07 DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.

Country Status (17)

Country Link
US (1) US8580832B2 (es)
EP (1) EP2134698A1 (es)
JP (1) JP2010520308A (es)
KR (1) KR20090128454A (es)
CN (1) CN101679327A (es)
AR (1) AR065657A1 (es)
AU (1) AU2008222755B2 (es)
BR (1) BRPI0808776A2 (es)
CA (1) CA2680212A1 (es)
CL (1) CL2008000667A1 (es)
EA (1) EA016887B1 (es)
IL (1) IL200759A0 (es)
MX (1) MX2009009520A (es)
NZ (1) NZ579417A (es)
TW (1) TW200902506A (es)
UA (1) UA98484C2 (es)
WO (1) WO2008109737A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
US20130040951A9 (en) * 2009-08-04 2013-02-14 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for cancer
WO2011019558A1 (en) * 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv Methods to measure dissociation rates for ligands that form reversible covalent bonds
WO2011019556A1 (en) 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND
CN102770429A (zh) * 2009-12-18 2012-11-07 詹森药业有限公司 用作雌激素相关受体-α调节剂的取代的氨基噻唑酮吲唑
CN102869660A (zh) * 2010-02-17 2013-01-09 詹森药业有限公司 作为雌激素相关受体-α调节剂的氨基噻唑酮
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
UY34244A (es) 2011-08-04 2013-02-28 Takeda Pharmaceutical Compuesto heterocíclico que contiene nitrógeno
CN104302322A (zh) 2012-03-26 2015-01-21 日本化学药品株式会社 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3050573B1 (en) 2013-09-25 2019-12-11 Nippon Chemiphar Co., Ltd. Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN120324396A (zh) * 2019-03-28 2025-07-18 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法
US20250268872A2 (en) * 2019-07-04 2025-08-28 Lead Pharma Holding B.V. Estrogen-related receptor alpha modulators
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
KR20220066822A (ko) 2020-11-16 2022-05-24 경북대학교 산학협력단 골 질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US20080313061A1 (en) 2004-06-30 2008-12-18 Paysetter Pte Ltd System and Method for Facilitating Transfer of Physical Money and/or Credit
KR20070041560A (ko) * 2004-07-14 2007-04-18 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 매개 질병 치료를 위한아릴리덴
EP1805154A4 (en) 2004-10-22 2009-11-25 Exelixis Inc PHARMACEUTICAL COMPOSITIONS

Also Published As

Publication number Publication date
IL200759A0 (en) 2010-05-17
EA016887B1 (ru) 2012-08-30
TW200902506A (en) 2009-01-16
EP2134698A1 (en) 2009-12-23
UA98484C2 (ru) 2012-05-25
AU2008222755A1 (en) 2008-09-12
CA2680212A1 (en) 2008-09-12
WO2008109737A1 (en) 2008-09-12
US20080221179A1 (en) 2008-09-11
AU2008222755B2 (en) 2013-05-02
EA200970839A1 (ru) 2010-04-30
KR20090128454A (ko) 2009-12-15
JP2010520308A (ja) 2010-06-10
BRPI0808776A2 (pt) 2014-08-19
US8580832B2 (en) 2013-11-12
MX2009009520A (es) 2009-11-18
NZ579417A (en) 2012-02-24
CN101679327A (zh) 2010-03-24
CL2008000667A1 (es) 2008-11-03

Similar Documents

Publication Publication Date Title
AR065657A1 (es) DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.
AR065656A1 (es) Tiazolidindionas n-alquiladas fenoxi sustituidas como moduladoras del receptor alfa relacionado con estrogeno
ECSP099614A (es) Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno
AR080207A1 (es) Aminotiazolonas como modulares de los receptores de estrogenos alfa
JP2010520308A5 (es)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
AR066904A1 (es) Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer
JP2014528466A5 (es)
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
JP2010508262A5 (es)
JP2010525023A5 (es)
JP2012526842A5 (es)
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
AR055202A1 (es) Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen
SI3166925T1 (en) Isoindoline derivatives for use in treating a viral infection
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
AR080206A1 (es) Aminotiazolonas como moduladores del receptor alfa relacionados con estrogeno
MX2025010782A (es) Compuestos de piridazina, su preparacion y sus usos terapeuticos
ES2945062T3 (es) Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer
AR076516A1 (es) Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1.
JP2008530242A5 (es)
NO20072418L (no) Arylsulfonylmetyl- eller arylsufonamidsubstituerte aromatiske forbindelser egnet for behandling av lidelser som reagerer pa modulering av dopamin D3-reseptoren
HRP20141065T1 (hr) Derivati difenil-sulfida i lijekovi koji ih sadrže kao aktivni sastojak
HRP20201615T1 (hr) Derivati etinila

Legal Events

Date Code Title Description
FA Abandonment or withdrawal